SOAT1 and Splenomegaly: By blocking the JAK-STAT signaling, ruxolitinib has demonstrated efficacy in reducing splenomegaly and improving constitutional symptoms in two large phase III studies (COMFORT trials) that enrolled patients at intermediate-2 and high IPSS risk [12, 13].